Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Ph 1 study for R/R Follicular Lymphoma March 18, 2024
AvantGen Receives Milestone Payment for First Patient Dosed in Ph 1 Study with Kite’s CAR-T Therapy March 12, 2024
Kite Receives U.S. FDA Approval Of Manufacturing Process Change to Reduce Median Turnaround Time For Yescarta March 4, 2024
FDA Accepts for Priority Review the Supplemental BLA for Epcoritamab (EPKINLY®) for Difficult-to-Treat R/R Follicular Lymphoma March 4, 2024
Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma February 26, 2024
Approval received to initiate clinical Ph 1/2-study CARMA with CAR T-cell therapy ELC-301 in B-Cell lymphoma February 26, 2024
Regulatory Applications Accepted in the U.S. and Japan for Breyanzi (lisocabtagene maraleucel) in R/R Follicular Lymphoma and R/R Mantle Cell Lymphoma February 26, 2024
First Patient Dosed in ALETA-001 Ph 1/2 Trial in Patients with R/R B-Cell Malignancies February 26, 2024
BLA for LYMPHIR™ (Denileukin Diftitox) For The Treatment Of Adults With R/R CTCL resubmitted February 26, 2024
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs January 31, 2024
First Dose Cohort in Ph 1 Trial of BP1002 to Treat R/R Lymphoma and R/R CLL Patients completed January 18, 2024
First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer January 18, 2024
Status of Ph 1/2 Study of ONCT-808 in Patients with R/R Aggressive B-cell Lymphoma announced January 10, 2024
Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom’s Macroglobulinemia Announced January 10, 2024
Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma announced January 10, 2024
Complete Response In First Lymphoma Patient Treated With MT-601 Following CAR-T Relapse December 19, 2023
FDA granted BTD and EMA application validated for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of R/R Follicular Lymphoma December 4, 2023
